Skip to main content
Engitix Therapeutics

Engitix Therapeutics Rating A · Worker

Engitix Therapeutics is a biotechnology company that develops drug discovery platforms and therapies targeting the extracellular matrix for chronic diseases.

Engitix Limited Healthcare London Website ↗

The UK Home Office lists Engitix Therapeutics as a licensed sponsor (A-rated, Skilled Worker route). They can sponsor work visas. We read every advert and list only roles that don't rule out sponsorship. Home Office figures released under the Freedom of Information Act show Engitix Therapeutics assigned 7 Certificates of Sponsorship in 2021–24 for Skilled Worker and Global Business Mobility visas. We're showing 2 of their current openings.

Sponsor licence details

Sourced from the UK Home Office register of licensed sponsors.

Licence rating
A
Worker · Active
Visa sponsorships
7
2021–24 · Home Office
Licensed
Since at least 2021
Headcount
51-200
55 total
Founded
2016
Open roles
2
Live on SponsorJobs
Sector
Healthcare
Location
London
Visa route
Skilled Worker

Sponsorship history

Certificates of Sponsorship Engitix Therapeutics assigned each year, from Home Office figures released under the Freedom of Information Act.

2021
1–5
2022
1–5
2023
1–5
2024
1–5
2025
—

Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.

About Engitix Therapeutics

Engitix Therapeutics is a biotechnology company specialising in drug discovery for chronic inflammatory diseases, fibrosis, and solid tumours. The company utilises its proprietary platform technology to decode the extracellular matrix, which is the structural scaffolding of human tissue that becomes altered during chronic disease.

By using tissue- and disease-specific human extracellular matrix scaffolds, the company models and studies the biological mechanisms driving these conditions. Engitix Therapeutics develops its own discovery-stage portfolio of therapeutic assets and collaborates with pharmaceutical and biotechnology partners to expand the application of its platform.

Open roles

2 live positions matched to this sponsor licence.